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1  | INTRODUC TION
The prothrombin time (PT) represents the most commonly used co-
agulation test and was first introduced into use by Dr Armand Quick 
and colleagues in 1935.1 The PT is a single-stage screening test used 
to evaluate the tissue factor (TF) and common coagulation path-
ways, and thus is affected by the activity of coagulation factors II 
(FII), V (FV), VII (FVII), X (FX), and fibrinogen.2 The test measures the 
time (in seconds) required for clot formation after thromboplastin re-
agent (a mixture of TF, lipids, and calcium chloride) is added to plate-
let-poor plasma (PPP). The classic model of coagulation, as reflected 
by the coagulation cascade, was first proposed scientifically in the 
1960’s, and divided into two pathways, one reflected by tissue factor 
activation of FVII (PT), and the other reflecting activation of the con-
tact pathway (APTT, activated partial thromboplastin time). These 
pathways converge to a common pathway, becoming linked through 
the production of thrombin by prothrombinase complex and the 
conversion of fibrinogen to fibrin by thrombin.2-4
Recent studies indicate that the TF pathway reflects the major 
driver of in vivo coagulation.2,5-7 A prolonged PT might be due to one 
or more coagulation factor defects in the TF or common pathways, 
or might indicate the presence of inhibitors against these factors.2,8 
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Abstract
The prothrombin time (PT) represents the most commonly used coagulation test 
in clinical laboratories. The PT is mathematically converted to the international 
normalized ratio (INR) for use in monitoring anticoagulant therapy with vitamin K 
antagonists such as warfarin in order to provide test results that are adjusted for 
thromboplastin and instrument used. The INR is created using two major PT ‘correc-
tion factors’, namely the mean normal PT (MNPT) and the international sensitivity 
index (ISI). Manufacturers of reagents and coagulometers have made some efforts 
to harmonizing INRs, for example, by tailoring reagents to specific coagulometers 
and provide associated ISI values. Thus, two types of ISIs may be generated, with 
one being a ‘general’ or ‘generic’ ISI and others being reagent/coagulometer-specific 
ISI values. Although these play a crucial role in improving INR results between labo-
ratories, these laboratories reported INR values are known to still differ, even when 
laboratories use the same thromboplastin reagent and coagulometer. Moreover, ISI 
values for a specific thromboplastin can vary among different models of coagulom-
eters from a manufacturer using the same method for clot identification. All these 
factors can be sources of error for INR reporting, which in turn can significantly af-
fect patient management. In this narrative review, we provide some guidance to ap-
propriate ISI verification/validation, which may help decrease the variability in cross 
laboratory reporting of INRs.
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In order to differentiate between coagulation factor deficiency and 
the presence of inhibitors, a mixing study is performed. If the PT 
is corrected after the addition of normal plasma, congenital, or ac-
quired coagulation factor(s) deficiency is implied, whereas, if the PT 
remains prolonged after the addition of normal plasma raises the 
possibility of inhibitors.8 Acquired defects of coagulation factors 
prolonging the PT are commonly observed in people with vitamin 
K deficiency.9 Alternatively, vitamin K antagonists (VKAs) such as 
warfarin, as prescribed to prevent thromboembolic events, hamper 
gamma-carboxylation of vitamin K-dependent coagulation factors 
(VKDCFs) and thus reduce their activity and also prolong PT.9,10 
However, in the case of VKAs, prolongation of the PT into a ther-
apeutic range is desired. Given that the synthesis of most coagula-
tion factors is restricted to the liver, disorders of this organ can be 
associated with a decrease of most coagulation factors, resulting in 
prolonged PT and/or APTT. Prolonged PT may also occur in patients 
with acquired FX deficiency due to amyloidosis, especially amyloid 
light-chain (AL) amyloidosis.10,11
Thromboplastin reagent is an essential component of the PT 
test. Thromboplastin reagent is a combination of TF, in complex with 
lipid surface of procoagulant membrane and calcium chloride ions. 
Thromboplastin reagents may be derived from human or animal 
tissues (brain or placenta), or through the production of recombi-
nant human TF within phospholipid vesicles.12,13 Use of different TF 
sources leads to variation in PT results reported by different labora-
tories. The significance of this emerged when North American coun-
tries used rabbit thromboplastin to monitor anticoagulation; this 
was less sensitive than the human thromboplastin reagents used in 
the UK and elsewhere.13,14 Due to the lower sensitivity of the rabbit 
thromboplastin, North American physicians prescribed higher doses 
of VKAs than the UK, as based on PT testing. However, the number 
of patients with bleeding in North American countries was about 5 
times that in Britain.13,14 For this reason, attempts to better stan-
dardize results of PT testing began in 1962, leading to the introduc-
tion of British Comparative Thromboplastin (BCT) as the reference 
thromboplastin in 1969.15 Following the standardization process, 
the World Health Organization (WHO) introduced the International 
Normalized Ratio System (INR) in 1983.16 This standardization sys-
tem provides a simple way to interpret PT results independently of 
the thromboplastin used.
1.1 | International normalized ratio (INR)
Over the past few decades, anticoagulation has seen tremendous 
and undeniable developments. Decades ago, patients in need of 
anticoagulant therapy had only a few options, including VKAs, and 
unfractionated heparin (UFH) to help manage and prevent throm-
bosis.17 Nowadays, there are much broader options for improving 
treatment and quality of life in these patients. A variety of low mo-
lecular weight heparins (LMWHs), heparin analogs and heparin-like 
compounds are available. In addition, direct oral anticoagulants 
(DOACs) have now been marketed for nearly a decade. Like VKAs, 
DOACs are also taken orally, but unlike VKAs, DOACs generally do 
not require regular laboratory monitoring of anticoagulation, and 
thus reflecting one of their main strengths.17,18 DOACs include fac-
tor Xa inhibitors (eg, apixaban, edoxaban, and rivaroxaban) and di-
rect thrombin inhibitors (dabigatran).19,20 Although various studies 
indicate general acceptance of these drugs, VKAs remain widely 
used, in part due to lack of experience in, and knowledge of, the 
newer drugs. In addition, some patients may not be good candidates 
for DOACs,17,20,21 and also because in some countries DOACs are 
seen as prohibitory expensive compared to VKAs. Nevertheless, due 
to differences in the preparation, source, and constituents of throm-
boplastin reagents, their sensitivity to monitoring and controlling 
VKAs - particularly warfarin - varies greatly. This difference can be 
large enough to require a change in patient management. Significant 
increases or decreases of VKA dose can increase the risk of throm-
bosis or bleeding if not appropriate to the situation.1,8,22
Initial efforts to standardize PT test results by reporting PT re-
sults as PT ratios were unable to completely resolve the issue of vari-
ability.13 The PT ratio, which is the patient's PT over a mean normal 
PT ratio, did not fully eliminate discrepancies between results: the 
test was still affected by variations in thromboplastin and could not 
be used to harmonize results for patients receiving VKAs.13 The INR 
instead reflects a mathematical calculation using a PT ratio as fur-
ther adjusted with a correction factor called the international sen-
sitivity index (ISI).1
According to WHO standards, an acceptable ISI value for throm-
boplastin reagents for manual methods is between 0.9 and 1.7.20 
However, due to a more severe decrease in FVII levels than other 
vitamin K-dependent coagulation factors, INR is not an appropriate 
index to evaluate the patient's condition at the onset of anticoagu-
lation with VKAs.23 Although INR is recommended for patients on 
VKAs, it is cannot harmonize PT results in patients with chronic liver 
disease. A modified INR, called INRliver is suggested by some authors 
for this purpose. In INRliver, plasma from patients with cirrhosis is 
used to calculate ISI of thromboplastin used.24
Although the INR tries to harmonize PT results according to 
process differences, the INR value is also influenced by other fac-
tors, including the type of coagulometer used and the value of the 
mean normal PT (MNPT) or geometric mean normal PT (GMNPT). 
Manufacturers of reagents and coagulometers have made some 
efforts to improve standardization, tailoring reagents to specific 
coagulometers. The reagents may designate two types of ISIs, the 
general (or ‘generic’) ISI and the reagent/coagulometer-specific ISI.25 
Commercial thromboplastins should be assessed and calibrated 
by their manufacturers against the WHO thromboplastin interna-
tional reference preparation (IRP). For this purpose, manual-tilt PT 
is typically performed, using a new or manufactured thromboplas-
tin and the reference thromboplastin, on 20 healthy subjects and 
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individual is considered to be therapeutically stable when treated 
with VKAs for at least 6 weeks.27 The values obtained from the man-
ufactured thromboplastin are plotted on the X-axis and the values 
from the reference thromboplastin on the Y-axis. The logarithm of 
these values is calculated and a line drawn with the best fit of the 
points obtained. The slope of the orthogonal regression line pro-
vides the ISI value (Figure 1).
In vitro monitoring of VKAs is required for many reasons, and the 
aim is to keep the INR in the range of 2-3 for most patients. However, 
a higher INR range may be required (eg, 2.5-3.5) for some patients 
at high risk of venous thromboembolism (VTE), and patients with 
mechanical heart valves. For this reason, clinically stable patients are 
usually monitored every 4-6 weeks and patients with unstable sta-
tus are monitored by PT/INR tests at shorter time intervals - every 
week or every few days.28,29
1.2 | Problems with monitoring of vitamin K 
antagonists
As mentioned earlier, a significant decrease in INR can increase the 
risk of thrombosis, mandating higher doses of VKAs. In contrast, a 
significant increase in INR represents an increased risk of bleeding, 
thus potentially indicating a reduction in the dose, temporarily dis-
continuing the drug, or if associated to very high bleeding risk (eg, 
INR > 10), reversing its effect by use of an antidote.30 This issue, and 
the need for regular drug monitoring, is among the accepted limita-
tions in the use and administration of VKAs. However, one less ap-
preciated, but important, issue is the accuracy or inaccuracy of the 
INR as reported by laboratories.31,32
Success or failure of treatment with warfarin is sometimes de-
termined by estimating the “time in therapeutic range” or TTR. The 
TTR index determines how clinically stable a patient is when receiv-
ing such anticoagulants, and thus could approximately determine 
whether VKAs are appropriate for any given patient.33-35
Although determination of reagent/coagulometer-specific ISI 
has played a large role in improving INR standardization, INR val-
ues reported by two laboratories may differ even with the same 
thromboplastin reagent and coagulometer. Moreover, the ISI value 
of a specific thromboplastin can vary among the different models of 
coagulometers of a particular manufacturer using the same method 
for clot identification.36,37 All these factors comprise sources of 
error for INR reporting, which in turn can significantly affect patient 
management.38 However, proper ISI verification and validation can 
decrease the rate of errors.
2  | THROMBOPL A STINS WITH A 
‘GENER AL’  IS I  VALUE
A general (or ‘generic’) ISI refers to an ISI value that is not specific to 
a particular coagulometer. This type of ISI is usually used identified 
for manual methods or coagulometers that use the same end-point 
clot detection method, for example, a manufactured thromboplastin 
for optical-based coagulometers or mechanical clot detection meth-
ods.39 Use of this type of ISI may lead to greater variability than rea-
gent/coagulometer-specific ISI values because even coagulometers 
that use the same clot detection method do not necessarily use the 
same principles (eg, differing mathematical algorithms). The error 
scale of the generic ISI, if not validated in the laboratory, is typically 
higher than that of reagent/coagulometer-specific ISIs. General ISI 
values should never be used clinically without prior validation in the 
laboratory.39-42
3  | THROMBOPL A STINS WITH RE AGENT/
COAGULOMETER-SPECIFIC ISI  VALUES
This type of ISI value is thromboplastin/coagulometer-specific, with 
reagents having individual ISI values for different coagulometer 
models. The ISI may differ more significantly between coagulom-
eters with different clot detection methods. Sometimes this differ-
ence can be noted across a company's coagulometers, even with the 
same clot detection method.42-44 Thus, different laboratories using 
identical reagents and coagulometers may identify significant differ-
ences in reporting INR values. For this reason, if the same sample is 
sent to different laboratories, different INR values will be reported. 
Although the difference in INR value is less than the PT value, even 
the existing level of variation in INR value can affect the physician's 
decision to change the treatment dose.44-46
If the thromboplastin manufacturer does not designate a re-
agent/coagulometer-specific ISI for the model used in a laboratory, 
the laboratory should not permit use of that specific thromboplastin 
for its own coagulometer without determination and verification of 
the instrument-specific ISI. In addition, each laboratory is obligated 
to verify even the asserted reagent/coagulometer-specific ISI of the 
manufacturer before using the PT reagent for clinical tests. In each 
case, if the verification process cannot confirm the asserted ISI, the 
F I G U R E  1   Calibration of the working thromboplastin solution 
(X-axis) against the international standard thromboplastin (Y-axis). 
Each dot represents the mean PT results (normal individuals and 
patients on VKA) interpolated on logarithmic paper. The slope of 
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reagent cannot be used for patient testing without ISI calibration 
and verification of calibrated ISI.26,42
4  | L ABOR ATORY ISI  C ALIBR ATION
4.1 | World Health Organization (WHO) 
recommended method
The World Health Organization (WHO) recommends this method 
for estimating ISI and GMNPT values for a new PT reagent by using 
a reference thromboplastin. To determine ISI and GMNPT of a new 
PT reagent, the laboratory should test the plasma of at least 20 
healthy subjects and 60 patients undergoing VKA therapy with sta-
ble clinical conditions.47 To determine MNPT, the plasma PT value 
of 20 to 40 normal individuals is determined and its geometric mean 
is calculated (ie, GMNPT).48 As in Figure 2, the logarithm of these 
numbers is plotted against the logarithm of the new PT results. The 
ISI is calculated as 1/slope of the regression line. Alternatively, one 
can replace the X- and Y-axes and then calculate the ISI based on the 
slope of the regression line.49
4.2 | Laboratory calibration of test system using 
certified plasma
Laboratory calibration can be performed using certified plasmas one 
of two different methods:
1. Calculation of laboratory ISI
2. Direct determination of INR (calculation of PT/INR calibration 
line)
Proper use of either of these methods can improve the accuracy 
of the INR report.
4.2.1 | Method of laboratory ISI calculation
This is a modification to the WHO-recommended method, and can 
be used in most laboratories.50 The PT value of each certified plasma 
is determined according to the reagent and the coagulometer in the 
laboratory and plotted on logarithmic paper against the determined 
INR for each citrated plasma. The slope of the regression line is used 
to determine the laboratory ISI. Orthogonal regression is the appro-
priate regression analysis.50,51
4.2.2 | Recommended method of the European 
Concerted Action on Anticoagulation (ECAA)
Another method is to use commercial plasma with a specified INR 
value. In this procedure, the INR of several commercial plasma sam-
ples is determined by the recommended WHO method or other, al-
ternative methods.52 These commercial plasmas can sometimes be 
used to determine the ISI, and perhaps even the GMNPT, for the 
new reagent/coagulometer combination, or to verify or reject a man-
ufacturer's asserted ISI. One alternative that is also approved by the 
FDA is that recommended by the ECAA Committee - the simplified 
WHO method.32 In this procedure, 27 artificially reduced lyophilized 
plasmas, including 20 factor-deficient plasmas and 7 normal plasmas 
were suggested. Indeed, because of the unavailability of stabilized 
patients under treatment with VKAs, the number of plasmas used 
in this procedure is greater than in other methods that use these 
patients for commercial plasma preparation. This is one of the limita-
tions of the ECAA's proposed method, which is performed manu-
ally with only one type of recombinant thromboplastin and a WHO 
human reference thromboplastin, and which may not to be suitable 
for all PT methods or all laboratories. In addition, one of the most 
important considerations when using certified or commercial plasma 
is that one should read the plasma guidelines before purchase to 
ensure that plasmas are suitable for the coagulometer and reagent 
used in the desired laboratory. Accordingly, the certified plasma 
specifies which commercial plasmas are usable for which devices. 
Moreover, if a laboratory uses recombinant human thromboplastin, 
it should ensure that certified commercial plasma is also verified for 
use with this type of thromboplastin.32,53
In this procedure, similarly to the WHO-recommended method, 
the logarithm of the INR values obtained by commercial calibrant 
plasma is plotted against the PT values obtained by the reagent/co-
agulometer combination. The ISI is calculated as 1/slope of the re-
gression line, as in the WHO method. The MNPT value is calculated 
as antilog of the y value.52,53
An alternative way to calculate ISI is by using the slope of the 
regression line, which can be used when replacing the X- and Y-axes 
is possible (Figure 3).
This alternative is also applicable and can be used in laborato-
ries, but it should be considered that the accuracy of this method 
depends on the accuracy of the INR values set for commercial cali-
brators by the manufacturers.
F I G U R E  2   How to achieve the ISI and MNPT values for a new 
reagent, based on the WHO method. The MNPT value is obtained 
by calculating the geometric mean of at least 20 normal individuals' 
plasma PT results. In this example, MNPT value is 12.8. The INR 
numbers are calculated by reference thromboplastin and are used 
for deriving reference INR. The ISI value is calculated by the slope 
of regression line, which in this example is 0.92 
Normal samples 
n ≥ 20, MNPT = 12.8 
Clinically stable patients 
on VKA therapy, n ≥ 60 
1/slope = 0.92 = calculated 
ISI. (Manufactured ISI = 
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5  | DIREC T DETERMINATION OF INR
This method of determining INR, first proposed by researchers from 
France, and latter modified in Clinical and Laboratory Standards 
Institute (CLSI) document,50,54 is independent of ISI and MNPT.54 
The PT test for commercially certified plasma is performed by a lab-
oratory coagulometer and reagent.54
This should be done within 3 days or three separate runs to min-
imize day-to-day and between-runs variations. The difference be-
tween the PT of a certified plasma must not exceed the permissible 
CV of the laboratory. If this number exceeds the designated CV, the 
test must be repeated for the certified plasma(s). The mean PT of 
each plasma is plotted on the Y-axis and the specified INR value of 
each certified plasma is plotted on the X-axis of logarithmic paper. 
The reference line is then drawn. This reference line helps to obtain 
a patient INR based only on a patient's PT values, without the need 
for ISI and MNPT values 54 (Figure 4).
6  | VERIFIC ATION OF INR RESULTS
Specific reagent/coagulometer ISIs should be verified prior to clini-
cal use in all laboratories using that ISI. For all laboratories using 
a generic ISI, verification is required and laboratory calibration is 
strongly recommended.42
7  | USAGE OF CERTIFIED PL A SMA S FOR 
VERIFIC ATION
It is recommended that at least three certified plasmas, covering the 
therapeutic dose of INR ranging from 1.5 to 4.5, be used to verify 
ISI. For some of these commercial certified plasmas, it is not pos-
sible to determine a single INR for all coagulometers. Before using 
these plasmas, one should read the instructions for these reagents 
to check the possibility of using these plasmas for their own test sys-
tem (combined set of reagent and coagulometer). If a new laboratory 
ISI is designated or a new calibration line is created for PT/INR, the 
test system must be validated prior to reporting patient results.50,51
8  | VERIFIC ATION METHOD
In the verification process, one can use certified or lyophilized 
plasma. The certified plasma INR value must be determined by the 
reagent and device used in the laboratory and by the ISI designated 
by the manufacturer.51 When certified plasma is used for verification, 
it should be used in duplicate tests for at least 2 days.50 According 
to the International Society on Thrombosis and Haemostasis (ISTH) 
standards, the INR obtained by the laboratory system with the INR 
determined by the company should not differ more than ± 15%.51 
All coagulometers used, even as support for PT testing, must be 
verified.52
9  | REQUIRED TIME INTERVAL FOR 
VERIFIC ATION
The verification process should be performed for each thrombo-
plastin with a general ISI. It is also recommended for thromboplas-
tins with reagent/coagulometer-specific ISI. The approval process 
should be re-performed following any changes to the reagent, lot 
F I G U R E  3   Demonstrates how to use commercial calibrators to 
determine ISI and MNPT for a new PT reagent. The INR values set 
for commercial plasma are considered as the reference INR values. 
Logarithm of these values is plotted against the logarithm of the 
PT number obtained by the reagent/coagulometer combination. 
ISI, which is 1.09 in this example, is calculated as 1/slope of the 
regression line. The MNPT is calculated as the antilog of the Y-axis 
with the X value considered to be zero. In this example, with 


























Log INR (commercial calibrant plasma)
Slope = 0.91; ISI for 
new reagent = 1/slope  = 
1.09
Y-axis intercept at X = 0.0 is 1.0499; antilog 
of intercept at X = 0.0 => MNPT = 11.2 
F I G U R E  4   How to obtain INR directly using commercial 
certified plasma. In this method, PT is determined for commercial 
certified plasma having an INR specified by the PT reagent and the 
laboratory coagulometer. The mean PT obtained for each verified 
commercial plasma is then plotted on the Y-axis on logarithmic 
paper and the assigned number corresponding to each verified 
plasma is plotted on the X-axis. The reference line is then drawn. 
For each patient, a PT test is performed, and from the Y-axis, 
the PT number line is connected first to the reference line, then 
perpendicular to the X-axis. The number that represents the 
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number, coagulometer, or any major overhaul of the coagulometer, 
all of which can change the PT, MNPT, and ISI values. If a significant 
change in quality control results, or a severe deviation is observed 
during external quality control testing, and the cause of the problem 
is not identified by standard and determined methods, the verifica-
tion process should be initiated,.42,51
10  | INTERPRETATION OF VERIFIC ATION 
RESULTS AND CORREC TIVE AC TIONS
Corrective measures should be considered if the results obtained for 
the INR by the laboratory differ from those determined by the com-
mercial plasma manufacturer (actual values) by more than ± 15% 
42,51,52 (Figure 5).
Firstly, one must ensure that the coagulometer is working 
properly and that the verification process has been done cor-
rectly.42,50 If the verification process was not achieved, laboratory 
calibration of PT/INR should be performed. The verified plasma 
used for calibration should be different from the verified plasma 
used for the verification process. After calibration, the verification 
process must be performed again, and if the results of the verifi-
cation process are acceptable, patient tests can be performed and 
reported.50,51
If the verification process still had unacceptable results, these 
corrective actions should be taken:
1. Evaluation of coagulometer performance
2. Evaluation of the test system with another thromboplastin
3. PT/INR calibration using a set of different verified plasmas
4. Contact with the certified plasma manufacturer and institution of 
recommended corrective actions.
11  | IMPAC T OF GOOD L ABOR ATORY 
PR AC TICE (GLP)  ON INR RESULTS
Good laboratory practice (GLP) can be considered an optimal labo-
ratory performance and ensures that INR results are correct. Best 
practices should also include50:
1. Ensuring that the coagulometer is maintained and used in ac-
cordance with the conditions specified by the manufacturer.
2. Ensuring that the laboratory method used to perform PT is fully 
controlled. It is important to make sure that the reagents used 
have not expired and all reagents are from one lot. Additionally, 
the laboratory must ensure that ISI and MNPT values have been 
correctly identified and incorporated into the INR formula.
3. Ensuring that reagents are maintained, prepared, and used in ac-
cordance with company instructions.
12  | CONCLUSIONS
Accurate reporting of PT/INR results has a direct effect on the 
management of patients undergoing VKAs therapy. An appropriate 
standardization process, can significantly improve the accuracy of 
reported results. Verification and if necessary, calibration of rea-
gent/coagulometer-specific, and generic ISIs, prior to clinical use is 
mandatory, and play a crucial role in improving PT/INR results.
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